Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Dec 9, 2023. (Total: 223870Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 6 (of 6 Records)

Query Trace: Vomiting and BRAF[original query]
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Jan 18 (2): 555-67.
Kirkwood John M, Bastholt Lars, Robert Caroline, Sosman Jeff, Larkin James, Hersey Peter, Middleton Mark, Cantarini Mireille, Zazulina Victoria, Kemsley Karin, Dummer Reinha
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Lancet (London, England) 2012 Jul 380 (9839): 358-65.
Hauschild Axel, Grob Jean-Jacques, Demidov Lev V, Jouary Thomas, Gutzmer Ralf, Millward Michael, Rutkowski Piotr, Blank Christian U, Miller Wilson H, Kaempgen Eckhart, Martín-Algarra Salvador, Karaszewska Boguslawa, Mauch Cornelia, Chiarion-Sileni Vanna, Martin Anne-Marie, Swann Suzanne, Haney Patricia, Mirakhur Beloo, Guckert Mary E, Goodman Vicki, Chapman Paul
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
The Lancet. Oncology 2013 Jul 14 (8): 733-40.
Robert Caroline, Dummer Reinhard, Gutzmer Ralf, Lorigan Paul, Kim Kevin B, Nyakas Marta, Arance Ana, Liszkay Gabriella, Schadendorf Dirk, Cantarini Mireille, Spencer Stuart, Middleton Mark
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
The Lancet. Oncology 2017 9 18 (10): 1307-1316.
Planchard David, Smit Egbert F, Groen Harry J M, Mazieres Julien, Besse Benjamin, Helland Åslaug, Giannone Vanessa, D'Amelio Anthony M, Zhang Pingkuan, Mookerjee Bijoyesh, Johnson Bruce
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
British journal of cancer 2017 Feb .
Bendell Johanna C, Javle Milind, Bekaii-Saab Tanios S, Finn Richard S, Wainberg Zev A, Laheru Daniel A, Weekes Colin D, Tan Benjamin R, Khan Gazala N, Zalupski Mark M, Infante Jeffrey R, Jones Suzanne, Papadopoulos Kyriakos P, Tolcher Anthony W, Chavira Renae E, Christy-Bittel Janna L, Barrett Emma, Patnaik Ami
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
ESMO open 2022 6 7 (3): 100506.
Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini
TOP